share_log

Reported Earlier, Roche's Genentech Presents Long-Term Data at ASH 2024 Highlighting Durable Remissions With Fixed-Duration Columvi And Lunsumio

Reported Earlier, Roche's Genentech Presents Long-Term Data at ASH 2024 Highlighting Durable Remissions With Fixed-Duration Columvi And Lunsumio

早前報道,羅氏的基因泰克在2024年ASH會議上展示了關於Columvi和Lunsumio固定療程治療的長期數據,突出了持久的緩解。
Benzinga ·  12/10 15:29

– Long-term data confirm fixed-duration Columvi and Lunsumio achieve durable remissions beyond the end of treatment, with real-world data suggesting reduced treatment-related travel burden due to less frequent dosing –

– 長期數據顯示,固定週期的Columvi和Lunsumio在治療結束後仍能實現持久緩解,現實世界的數據表明,由於劑量減少,治療相關的旅行負擔減輕 –

– First presentation of Lunsumio given subcutaneously showed non-inferiority to intravenous treatment with a consistent safety profile, potentially providing an additional outpatient option with a shorter administration time –

– Lunsumio的首次皮下注射展示了與靜脈治療的非劣效性,並具有一貫的安全性,可能提供一種額外的門診選擇,具有更短的給藥時間 –

– Positive results for Genentech's two bispecifics antibodies validate the company's efforts to provide multiple treatment options that suit the diverse needs of lymphoma patients and healthcare providers –

– Genentech的兩種雙特異性抗體的積極結果驗證了該公司提供多種治療選擇的努力,以滿足淋巴瘤患者和醫療服務提供者的不同需求 –

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論